Quantitative In Situ Analysis of the Human Anterior Cruciate Ligament and Midsubstance Cross Sectional Area

Y. Fujimaki,Eric D. Thorhauer,C. Murawski,Y. Sasaki,P. Smolinski,S. Tashman,Freddie H. Fu

Abstract:

What problem does this paper attempt to address?

P650 Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world

A Mínguez,E Coello,M Gomez,P Ripoll,A Garrido,M Aguas,M Iborra,E Cerrillo,L Tortosa,V Bayarri,P Nos,G Bastida

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0780

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is an effective treatment for Crohn's disease (CD) and ulcerative colitis (UC). However, some patients do not respond to conventional subcutaneous (SC) doses and lose response at follow-up. The use of maintenance intravenous (IV) UST could play a role in these patients. Methods The aim of the study was to evaluate the effectiveness of IV maintenance UST in patients with failure to subcutaneous UST. Single-center study performed in consecutive patients included in a prospective database. The reduction of activity markers such as C Reactive Protein (CRP) and fecal calprotectin (FC), UST trough levels pre- and post IV maintenance as well as clinical indices of activity were evaluated. IV dose adjustments and their effect on levels were collected. We defined biochemical remission as the percentage decrease FC ≥ 80% and/or final FC ≤ 250. Results Of 335 patients in our center under treatment with ustekinumab, 31 patients (9.25%) were included. Baseline characteristics of patients are shown in Table 1. Mean age at the start of UST IV 42.49 years ± 13.23. CD 77.4%; UC 22.6%. Up to 2/3 of patients with CD had a complicated phenotype (B2/B3) and 50% perianal disease (PD). All included patients were bio-exposed and 61.3% had carried ≥ 2 biologics. The major indication for initiation of UST was secondary failure to previous biologic therapy (74.2%). The most used induction IV dose was 390mg and subsequent SC maintenance was every 8 weeks in 76% (60% were later intensification cases). Re-induction was performed in 36.7% of patients. The median time from drug initiation to IV maintenance was 10.23 [IQR 30.7] months. In 54.8% a higher dose was administered in the first IV maintenance infusion. The most common maintenance regimen was 130mg (64.5%) every 4 weeks (54.8%). Baseline FC decreased significantly (Figure 1) at the end of follow-up (median [IQR]: 809 μg/g [2256] vs 333 μg/g [508], p =0.001). Basal Harvey index was reduced compared to HBI at 24 weeks (mean ± SD: 6.5 ± 4.3 vs 4.1 ± 3.1, p =0.019). Drug levels at the start of IV maintenance were 1.4 μg/ml [IQR 2.3] vs. 4.8 μg/ml [IQR 3.9] at week 24 (p< 0.001) after dose adjustment in 35.5% of patients during IV maintenance. At the end of follow-up 54% went into biochemical remission. The presence of PD was associated with lower biochemical remission (70.6% vs. 27.3%, p =0.025). The median IV UST maintenance time was 8.55 [IQR 23.9] months. 96.6% are continuing treatment. No serious infections or malignancy were documented. Conclusion The use of maintenance IV UST appears to be an effective and safe strategy that can be evaluated as a salvage treatment especially in highly bioexposed patients or with complex CD phenotype.

gastroenterology & hepatology
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing

Federico Argüelles-Arias,Teresa Valdés Delgado,Belén Maldonado Pérez,Jaime González Antuña,Luisa Castro Laria

DOI: https://doi.org/10.1177/17562848231191670

2023-08-24

Abstract:Background: Ustekinumab (UST) is indicated for the treatment of Crohn's disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) maintenance has been proposed. Objectives: The primary endpoint of our study was to evaluate the efficacy and safety of maintenance IV UST treatment in Inflammatory Bowel Disease (IBD) patients who present with partial response or loss of response to subcutaneous (SC) UST. Design: We performed a monocentric observational retrospective study including patients with active IBD on maintenance treatment with IV UST. Methods: The clinical response and remission was analyzed at week 12, defined as either Harvey-Bradshaw Index ⩽ 4 for CD or partial Mayo Score ⩽ 2 for UC. The reduction of objective markers of disease activity, fecal calprotectin, and C-reactive protein was evaluated. Moreover, UST trough levels were measured pre- and post-UST IV maintenance and any adverse events were assessed. Results: We included 23 patients. Clinical remission at week 12 was achieved by 43.5% of the patients. The proportion of patients in clinical response after 12 weeks on UST IV maintenance was 82.6%. After a median follow-up of 9.3 months all patients remained on IV UST maintenance. No adverse events were recorded in any patient for the duration of the study. Conclusions: IV UST maintenance treatment was able to recapture response in most of the patients who had lost response to SC maintenance.
P740 Results at 52 weeks of Intravenous Ustekinumab as Maintenance Treatment in Patients with Loss of Response to Subcutaneous Doses: A Multicenter Retrospective Observational Study

T Valdés Delgado,J González Antuña,F Javier Rodriguez González,F Gutierrez Martinez,B Maldonado Pérez,L Castro Laria,M Belvis Jiménez,Á Caunedo Álvarez,G Alcain Martinez,R Camargo Camero,J V Martos Van Dussen,A Fernández Castañer,F Argüelles-Arias

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0870

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is indicated for the treatment of Crohn’s Disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world,some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) maintenance has been proposed. The primary endpoint of our study was to evaluate the efficacy and safety of maintenance IV UST treatment in Inflammatory Bowel Disease (IBD) patients who present with partial response or loss of response to subcutaneous UST. Methods We performed a multicenter observational retrospective study including patients with active IBD on maintenance treatment with IV UST. The study conducted at 2 hospitals in Andalusia.The clinical response and remission was analyzed at week 12 and 52, defined as either Harvey-Bradshaw Index (HBI) ≤4 for CD or partial Mayo Score (pMS) ≤2 for UC. The reduction of objective markers of disease activity, fecal calprotectin (FCal) and C-reactive protein (CRP) was evaluated. Moreover, UST trough levels were measured pre-and post UST IV maintenance, drug persistence at the end of the follow-up and any adverse events were assessed. Results A total of 59 patients were included in the study, with a median age of 41 years [IQR32-52]. 84.7% (50/59) had Crohn's disease (CD). 91.5% (53/59) had previously received at least one biologic or JAK inhibitor treatment. 58.6% (34/59) werepreviously on subcutaneous UST every 4 weeks (Table 1). In patients with CD, the median baseline HBI value was 9 (IQR 6-12), which decreased to 5 (IQR 4-7) at week 12 and 4 (IQR 3-6) at week 52 (p<0.001) (Figure 2A). In patients with ulcerative colitis (UC), the median baseline pMayo value was 8.5 (IQR 6.5-9.0), which decreased to 5.5 (IQR 4.3-6.0) at week 12 and 3 (IQR 2.0-4.8) at week 52 (p=0.017) (Figure 2B). The median baseline FCal was 800.2 μg/g, which decreased to 520 μg/g at week 12 and 220 μg/g at week 52 (p<0.001). Regarding CRP, the median baseline was 7.1 mg/L, which decreased to 4 mg/L at week 12 and 3 mg/L at week 52 (p<0.001). The median UST levels with subcutaneous maintenance treatment were 3.1 mcg/mL (IQR 1.1-7.4) compared to 12 mcg/mL (IQR 9-20) with intravenous treatment (p<0.001) (Figure 2C). Clinical remission at week 12 and 52, was achieved by 47,5% and 64,3% of the patients respectively. At the end of the follow-up, 96.6% of the patients continued with intravenous UST (Figure 2D). No adverse events were recorded in any patient for the duration of the study. Conclusion Intravenous UST for maintenance is able to rescue up to 64% of patients who have failed on subcutaneous doses. 97% of patients continue intravenous UST treatment after one year with an excellent safety profile. UST levels increase fourfold.

gastroenterology & hepatology
P895 Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel Disease

B López-Sáez,E Brunet-Mas,L Melcarne,A Puy,S Lario,M J Ramirez-Lázaro,L P Llovet,B Garcia-Sagué,L E Frisancho,A Altadill,A Villoria,X Calvet

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1025

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is a monoclonal antibody that inhibits the p40 subunit of IL-12 and IL-23, approved for the treatment of Crohn's Disease (CD) and Ulcerative Colitis (UC). Its administration is intravenous during induction and subcutaneous during maintenance. Several studies have assessed the efficacy of reinduction and intensification of this treatment in patients with loss of response. However, there are few studies evaluating the effectiveness of intravenous UST for maintenance. The aim of the study is to evaluate the efficacy and safety of maintenance with intravenous UST in patients with Inflammatory Bowel Disease (IBD). Methods Observational, retrospective, and single-center study. All patients receiving maintenance with intravenous UST until June 2023 were reviewed. Clinical response was evaluated with Harvey-Bradshow Index for CD and partial Mayo for UC. Biochemical response was evaluated with calprotectin and C-reactive protein. Results A total of 29 patients with IBD (24 CD and 5 UC) were included. The mean follow-up of patients was 449 days (74-948). The cohort's characteristics are summarized in Table 1. In all cases, intravenous maintenance was performed with UST 130mg/4 weeks. In 4 cases (13.8%), maintenance was initiated directly with intravenous UST. In 9 (31%) patients due to primary failure to UST and in 16 (55.2%) patients due to secondary failure. The clinical response to intravenous UST maintenance in patients with CD at week 8 and 16 and at one year of follow-up was 87.5% (n=21/24), 83.3% (n=20/24), 73.3% (n=11/15) respectively. For UC, the response was 60% (n=3/5) at week 8 and 16 and at one year. The drug survival was 723 days (± 74) (Figure 1). No predictive variable for treatment response was identified. Two patients (both with CD) experienced recurrent respiratory infections as an adverse effect, without the need to discontinue UST. Conclusion Maintenance treatment with intravenous UST can be useful and safe in patients with severe IBD and/or failure of subcutaneous UST maintenance.

gastroenterology & hepatology
P994 Single center assessment of intravenous ustekinumab maintenance in Crohn’s disease

S J Fernández Prada,E A Fuentes-Valenzuela,J Barrio Andrés,Á De Prado Santos,M Á Marinero Muñoz,R Calleja Carbajosa,F J García Alonso

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1124

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is usually employed in Crohn’s disease (CD) after anti-tumor necrosis factor (TNF) therapy failure or if anti-TNF therapy is contraindicated. Higher UST trough levels have been associated with better clinical/endoscopic outcomes, so dose escalation (reducing dosing intervals or reinduction) is widely used. Intravenous (iv) maintenance has been proposed, but it has been barely assessed. Methods Single center, retrospective case series. All patients with CD starting treatment with UST and receiving at least one dose were eligible. Subjects started on UST in other centers or those prescribed for any indication different than IBD were excluded. Dose escalation to iv maintenance was performed in case of lack or loss of response or persisting significant inflammation in laboratory tests, imaging or endoscopy. Following dose escalation, Harvey Bradshaw Index (HBI), fecal calprotectin and C reactive protein (CRP) were checked at each visit. UST trough levels were also assessed. Primary outcomes were clinical remission (HBI<5) and biochemical remission (fecal calprotectin <250 mg/kg). Adverse events, and treatment persistence were also assessed. Results A total of 131 patients treated between May 2017 and August 2023 were included. Sixty (45.8%) patients were escalated to iv UST maintenance after a median of 14.1 (IQR: 8-50.4) weeks of UST treatment. Baseline characteristics are shown in table 1. Patients were started on iv UST maintenance due to persistent inflammatory activity in imaging/endoscopic procedures in 21 (35%), clinical response without remission in 17 (28.3%), low trough concentrations in 16 (26.7%) and primary non-response in 6 (10%). Thirty-three (55%) were receiving sc UST every 4 weeks and 23 (38.3%) started iv maintenance directly after UST induction. At initiation of iv maintenance, patients presented a median HBI index of 4 (IQR: 2-7), a fecal calprotectin of 514 (IQR: 213-1078) mg/kg and UST trough levels of 4.8 (IQR: 3-7.3) μg/mL. Following iv maintenance, UST trough levels increased to 10.9 (IQR: 8-17.4). Clinical remission rates increased from baseline (48.3%) at weeks 8 (79.6%, p=0.001), 24 (72%, p=0.01) and 48 (74.4%, p=0.01). However, the 10-13% increase observed in the biochemical remission rates was not statistically significant (figure 1). Treatment persistence 2 years after starting UST iv maintenance was 72.2% (95% CI: 54.7-83.8%). Only 2 infectious adverse events were observed in the whole cohort (2/131, 1.6%), both in patients receiving sc maintenance. Conclusion UST iv maintenance in bio-experienced patients is safe and increases clinical remission rates, although it did not achieve a relevant improvement in biochemical remission rates.

gastroenterology & hepatology
P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients

L Ramos Lopez,R Ramos-Díaz,F Benítez-Zafra,A Morant-Domínguez,B Vera-Santana,I Mourani-Padrón,I Alonso-Abreu,M Carrillo-Palau,C Reygosa,J S Medina-Chico,F Gutierrez-Nicolás,J Nazco-Casariego,M Hernández-Guerra

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0993

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Therapeutic drug monitoring (TDM) serves as a valuable tool for improving efficacy and reducing rates of drug toxicity .However, the utility of TDM with non-anti-TNF agents (such as Ustekinumab-UST) is less well defined, although it may be useful in optimizing UST posology and improving efficacy. In this study, we aimed to evaluate clinical outcomes and UST plasmatic concentration in real-world IBD patients. Methods A prospective study was conducted including IBD patients who initiated UST therapy between August 2020 and June 2023. Clinical outcomes were prospectively collected (clinical remission as Harvey-Bradshaw Index (HBI) <4 or partial Mayo score (pMS)≤1; biochemical remission as fecal calprotectin (FC)<150 g/kg); physician global assessment (PGA) (active/ not active) and patient-reported outcome (IBDQ-9)) and UST plasmatic concentration was assessed by ELISA every 8 weeks for 12 months. The need for drug escalation, surgery, hospitalization, or discontinuation of treatment at the end of the follow-up (September 2023) was recorded. Results A total of 91 patients were included (population described in Table 1). After a median follow-up of 12 (9.6-10.7) months, clinical remission was observed in 90.4% of CD and 66.6 % of UC patients, 52.7% presented biochemical remission and 61.5% of IBD patients were inactive by PGA. 81% of patients showed a good quality of life as measured by IBDQ-9 >60 points. 9.9% needed IBD hospitalization and only 1 (1.09%) patient required IBD surgery. UST-dose escalation was indicated for 33% of patients, mainly in UC patients (UC 46.1% vs CD 28.1%; p=0.42). Treatment discontinuation was required in 13.2% (12/91) of patients after a median follow-up of 15 (14.8-19) months, due to loss of response in 66.6% of these patients (Figure 1A). The mean UST concentration at induction (8 weeks) was significantly higher than at maintenance (16 weeks) (9.2 (7.7-10.7) μg/ml vs 4.8 (3.9-5.7); p>0.0001); no differences in UST concentration were found during the maintenance treatment (Figure 1B). UST concentration was not related to age, sex, body mass index, type of IBD, or previous exposure to biological agents. In multivariate analysis, UST concentration >7 μg/ml in maintenance (16 weeks) showed an independent predictive value for IBD hospitalization (OR 7.6, 95% CI 2.5-23.1) and UST-dose escalation (OR 4.1, 95% CI 1.4-11.9) in the next 12 months. Conclusion Ustekinumab (UST) is an effective treatment, bringing about clinical remission and an enhanced quality of life for individuals with inflammatory bowel disease (IBD). In our prospective cohort, UST concentration at maintenance serves as a predictive indicator of IBD outcome.

gastroenterology & hepatology
P605 Intravenous Ustekinumab maintenance treatment is effective in patients with Crohn’s Disease

Y Wang,Y Chen

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0735

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background With the usual subcutaneous (SC) doses (90 mg every 8-12 weeks) of Ustekinumab some patients will only partially respond or experience secondary loss of response. Intravenous (IV) dose of Ustekinumab is more affordable than the subcutaneous does in China. However, the evidence of intravenous administration maintenance when shortening subcutaneous dose is not effective enough is limited. Methods We conducted a retrospective study to evaluate the effectiveness and safety of IV Ustekinumab in patients with Crohn ́s disease (CD). Patients received Ustekinumab with insufficient efficacy or loss of response to 90 mg SC treatment could escalate to IV maintenance at regular intervals through every clinic visit and could deescalate back to SC maintenance when the efficacy is satisfied. We obtained data from 247 patients. Results Follow-up data beyond 24 weeks (24w) were available for 229 patients and data beyond 52 weeks (52w) were available for 144. Baseline characteristics of the included patients are shown in Table 1. Complicated forms (B2-B3; 55.6%) predominated and perianal disease was present in 45.3% of patients. 136(58.12%) patients were naïve to biological treatments, 41.8% had received at one and 8.97% more than 2. Steroid-free clinical remission were observed in 88.1%(185/210) patients at 24 weeks.35/104(33.65%) had a normal level of fecal calprotectin(FCP) and 56/115(48.70%) achieved endoscopic remission at 52 weeks. Serious adverse events were reported in 0.81% of patients. Logistic regression demonstrated that 24w C-reactive protein, baseline FCP and frequency of IV treatment were associated with endoscopic remission at 52w (Figure 1). Conclusion Patients who lose response to the intensified dose of Ustekinumab SC could benefit from intravenous administration as maintenance treatment.

gastroenterology & hepatology
P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort

A Aparicio-Serrano,J M Zamora Olaya,D S Ortiz Chimbo,M I Rodríguez Tirado,A Gómez Pérez,P Soto Escribano,S Marín Pedrosa,E Iglesias Flores,J M Benítez

DOI: https://doi.org/10.1093/ecco-jcc/jjab232.461

2022-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background To evaluate the short and long-term effectiveness and safety of ustekinumab (UST) in a real-world multirefractory Crohn’s disease (CD) cohort. Methods An observational, retrospective and single-center study of CD patients treated with UST since June, 2017, with at least, 16 weeks of treatment. All patients were identified in the ENEIDA Registry. Demographic, disease, and outcome variables were collected. Clinical remission and response (measured by the physician global assessment and Harvey Bradshaw Index (HBI) score) as well as biological response (measured by C-reactive protein (CRP) and fecal calprotectin) were evaluated at weeks, 16, 26, 52 and at the end of the follow-up. Kaplan-Meier survival curves were performed to analyze drug persistence and multivariate analysis to identify predictors of response. Treatment-related adverse events were assessed. Results 64 patients included, mean age of, 49 years (35–60), 56.2% men and CD duration of, 15.5 years (8–22)., 53% had ileocolic involvement and, 59% stricturing and/or penetrating disease., 40% presented perianal disease, 35% active smoking and, 33% patients had extraintestinal manifestations., 92.2% had prior failure to biologics (44% failed at, 1 and, 48.5% failed 32) and, 9.4% had failed to vedolizumab., 57.8% required prior surgery for IBD., 40.6% initiated UST for treatment of postoperative recurrence. Baseline clinical activity was present in, 87.5% patients (60% moderate-severe activity). Rates of clinical remission, response and no response were, respectively, 40.7%, 47.5% and, 12% at week, 16;, 56.8%, 32.8% and, 10.3% at week, 26;, 60%, 30% y, 10% at week, 52. At the end of the follow-up, more than, 2/3 of patients (76.3%) had clinical response or remission (figure 1). Overall, a significant reduction of HBI score was observed from baseline to week, 16 and maintained at W26 and W52 (figure 2). Likewise, a biological response was observed with a significant reduction of CRP (baseline of, 26.7 mg/dL) at different times of evaluation (figure 3)., 74.9% continued with UST for up to three years (figure 4). In the multivariate analysis, the only independent factor associated with non-response was previous therapy with vedolizumab (OR:, 0.055 [IC95%:, 0.005–0.551], p=0.001). The safety profile was favorable; only, 2 patients (3.1%) stopped the drug due to side effects (arthralgias and bladder neoplasia). Fig, 1. Remission, response, and no response rates. Fig, 2. Evolution of HBI score from baseline to W52. Fig, 3. Evolution of CRP from baseline to W52. Fig, 4. Persistence of ustekinumab during the follow-up period. Conclusion UST is effective and safe in a real-life refractory CD cohort, with a persistence of the drug of, 75% at, 3 years. Previous vedolizumab therapy is associated with UST treatment failure.
High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease

Jaime González-Antuña,Teresa Valdés-Delgado,Belén Maldonado-Pérez,María Belvis-Jiménez,Luisa Castro-Laria,Vicente Merino-Bohórquez,Miguel Ángel Calleja-Hernández,Paula Castro-Martínez,Cloe Charpentier,Federico Argüelles-Arias

DOI: https://doi.org/10.1177/17562848241271980

2024-09-09

Abstract:Background: Ustekinumab (UST) is an effective treatment option in Crohn's disease (CD) and ulcerative colitis (UC). However, it still remains unclear if therapeutic drug monitoring could be helpful to guide clinicians. Objectives: The aim of our study was to analyze the relationship between UST through levels (USTTL) and clinical outcomes in real-world inflammatory bowel disease (IBD) patients. Design: We performed a unicentric retrospective study including patients with IBD under UST treatment with at least one level determination. Methods: The following variables were analyzed at the initiation of UST and at each USTTL measurement: clinical response and remission using the Harvey-Bradshaw Index (HBI) for CD and the Partial Mayo Score (pMayo) for UC; biochemical response and remission using fecal calprotectin and C-reactive protein, among others. Two periods were considered: P1 (time between induction and the first determination of USTTL) and P2 (time between USTTL1 and the second determination of USTTL). Results: We included 125 patients, 117 with CD. In P1, 62.4% of patients were on subcutaneous maintenance, and the median USTTL1 was 3.1 μg/mL (1.6-5.3). In 44.8% of CD patients (48/117), clinical remission was achieved, with USTTL1 significantly higher than those who did not achieve remission (3.7 μg/mL (2.3-5.4) vs 2.3 μg/mL (1.1-5.2); p = 0.04). In the 46 patients with two determinations, statistically significant differences were found between variables in P2 versus P1: clinical remission (73.9% vs 21.7%; p = 0.001); USTTL (7.2 μg/mL (4.7-11.7) vs 3.4 μg/mL (1.9-6.4); p < 0.001), HBI (4 (4-4.3) vs 8 (4-9); p < 0.001), pMayo (1 (1-3.3) vs 4.5 (3-5); p = 0.042), and corticosteroid use (26.1% vs 41.3%; p = 0.024). Receiver-Operating-Characteristic (ROC) curves were calculated for clinical remission in P2, with USTTL cutoff value of 6.34 μg/mL for clinical remission and a high rate of intensified patients (98%). Conclusion: High serum levels of UST were associated with clinical remission during treatment for IBD under intensification treatment, with a cutoff point of 6.3 μg/mL.
DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study

M Chaparro,S Hermida,D Acosta,A Fernández-Clotet,M Barreiro-de Acosta,Á Hernández Martínez,M Arroyo,M M Bosca-Watts,M T Diz-Lois Palomares,L Menchén,J Martínez Cadilla,E Leo-Carnerero,C Muñoz Villafranca,M Sierra-Ausín,Y González,S Riestra,P Sendra Rumbeu,M J Cabello Tapia,I García de la Filia,E Montil Miguel,D Ceballos,R Pajares Villarroya,P Ramírez de la Piscina,M D Martín-Arranz,L Ramos,A Ruiz-Cerulla,M P Teresa de Jesús,E San Miguel,X Calvet,J M Huguet,A Keco-Huerga,R H Lorente Poyatos,J F Muñoz,Á Ponferrada,B Sicilia Aladrén,P Delgado-Guillena,E Gómez Delgado,F J Rancel-Medina,H Alonso-Galán,J P Gisbert

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0114

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Primary aim: To assess the durability of ustekinumab treatment in patients with ulcerative colitis (UC). Secondary aims: To assess the short-term effectiveness, the durability of response, and the tolerability of ustekinumab in clinical practice. Methods Retrospective, multicenter study including UC patients who had received the 1st ustekinumab dose at least 16 weeks before inclusion. Patients were followed-up from the 1st ustekinumab dose to treatment discontinuation or last visit. Only patients with active disease [Partial Mayo Score (PMS)>2] at ustekinumab start were considered in the effectiveness analysis. Clinical effectiveness was based on PMS. Patients who stopped ustekinumab before their last visit were considered not in remission at subsequent time points (negative imputation). Results 620 patients were included (table 1). 78% of patients who started ustekinumab maintenance treatment, did it with 90 mg every-8-weeks dose. 155 patients (25%) withdrew ustekinumab during follow-up [median=12 months (m)]. Incidence rate of ustekinumab discontinuation was 20% per patient-year of follow-up. The probability of maintaining ustekinumab is shown in figure 1A. Among patients who withdrew ustekinumab, the main reasons were primary non-response (39%) and loss of response (35%). Anaemia at baseline (HR=1.5, 95%CI=1.1-2.1), steroids at baseline (HR=1.5; 95%CI=1.06-2.08), and more severe clinical activity at baseline (HR=1.5; 95%CI=1.09-2.06) were associated with higher risk of ustekinumab discontinuation. Short and long-term effectiveness of ustekinumab is shown on figure 1B. Moderate-severe vs. mild disease activity at baseline (OR=0.3, 95%CI=0.2-0.5), male sex (OR=0.5; 95%CI=0.4-0.8), and increased number of previous biologics (OR=0.6, 95%CI=0.6-0.8) were associated with lower likelihood of steroid-free remission at week 16. A total of 57 (25%) patients among those with active disease at baseline and with steroid-free remission at week 16, lost response during a median follow-up of 8 m (IQR=3-16 m) (figure 1C). The dose was escalated in 72% of patients with loss of response, and 80% improved (67% remission); an intravenous reinduction was given in 3 patients, and none of them improved. A total of 176 patients (28%) had at least one adverse event, with infections being the most frequent (11%). No negative impact on extraintestinal manifestations and/or immunomediated diseases was seen. Conclusion Ustekinumab was effective in inducing remission even in highly refractory UC patients. A proportion of patients discontinue the treatment, mostly due to primary failure and loss of response. Dose escalation may be effective to regain response after loss of effectiveness. The safety profile was similar to previously reported.

gastroenterology & hepatology
P528 Re-induction of intravenous ustekinumab to maintain drug persistence. A UK experience

J Muir,Y Hazir,J Butterworth

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0658

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background In this study we seek to add to the body of knowledge on the practical use of ustekinumab in patients with Crohns and Colitis. Patients commencing ustekinumab will mostly have failed, or are intolerant to, conventional biologic agents and therefore have a limited number of medical options available to manage their disease. Results from the IM-UNITI long-term extension study have shown that a proportion of patients will lose response to maintenance dose therapy, and a small number of studies have suggested that repeated induction doses of this therapy can prolong its effective use and allow patients a greater period of disease free remission. Shrewsbury and Telford hospital NHS trust is a multi-site UK hospital serving a large population in the west-midlands region which has established the routine use of usetkinumab therapy over 5 years ago and by reviewing data on our patient cohort we aimed to identify characteristics amongst patients who have required reinduction doses and how effective they have been in maintaining remission. Methods In this retrospective, interventional study two researchers gathered data including baseline characteristics, disease type and distribution, previous surgical and medical therapies and time from diagnosis on all patients who had received ustekinumab therapy over the past five years. We used biochemical and endoscopic data, as well as clinical records, to determine the efficacy of ustekinumab on the disease course. We identified the subgroup of patients requiring reinduction doses and noted whether this was a successful intervention and sought to describe similarities which could help identify patients at risk of failing maintenance therapy in future. Results Data from 213 patients was gathered (Crohns: 150, UC: 61, IBDU: 2) and of which 87 (Crohns: 63, UC: 24) received reinduction doses. Average time to reinduction from therapy commencement was 19.5 months (Crohns) and 16.3 months (UC) respectively. Of the reinduction group 63% showed improvement in their disease control and a variety of characteristics were noted amongst the successful patients for discussion including disease location, presence of perianal disease and time from diagnosis. Conclusion Ustekinumab reinduction is an important area for further research as it allows patients to prolong their successful therapy and delay the need for surgical intervention for difficult to manage disease. This study suggests characteristics which could inform further trials and establish protocols to aid clinicians when making decisions about switching biologic therapies.

gastroenterology & hepatology
P531 Long-Term Evaluation of Intensified Ustekinumab in Crohn's Disease: Real-Life Results

G Molina Arriero,T González Furelos,V Mauriz Barreiro,A Echarri Piudo

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0661

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Dose intensification of ustekinumab (UST) is implemented in clinical practice to rescue patients with loss of response or suboptimal clinical response to the drug. Observational studies, with contradictory results, associate higher UST trough concentration and clinical outcomes in Crohn's disease (CD). The primary outcome was to evaluate the long-term effectiveness of dose intensification of UST in terms of clinical and biochemical remission and its relationship with serum trough concentrations. Methods A retrospective, single-center observational study was conducted, including patients with CD treated with intensified UST, analyzed from January 2023 to the present. Demographic data, smoking status, disease pattern and duration, extraintestinal manifestations, perianal disease, and prior exposure to biologics were collected. Laboratory markers (fecal calprotectin (FCP) and C-reactive protein (CRP)), disease activity scores (Harvey-Bradshaw Index (HBI)), and drug serum levels at the time of intensification, at 6 and 12 months, were analyzed to evaluate response. Clinical remission was defined as HBI < 5, clinical response was defined as reduction in the HBI by ≥3 points and biochemical remission as FCP < 150 μg/g. Data were collected from the electronic medical record. Quantitative variables were expressed as median (interquartile range). To analyze the results, a logistic regression was performed. Results A total of 35 patients were included. Patients' clinical and demographic characteristics are summarized in Table 1. All were intensified with subcutaneous dose of 90 mg every 4 weeks (31.4% underwent intravenous re-induction). At 6 months after UST intensification, 82.86% (n=29) of the patients presented clinical remission, with a statistically significant decrease in FCP levels (247.78 μg/g vs. 133.55 μg/g (p = 0.0026)). At 12 months, 85.71% had achieved clinical remission, also presenting a statistically significant decrease in FCP levels (370.41 μg/g vs. 200.94 μg/g (p = 0.0200)). Drug levels, classified as >2.2 μg/ml and <=2.2 μg/ml, were not related to remission at 6 months (OR 0.94, 95%CI 0.05-16.35. p=0.97) or at 12 months (OR 0.87, 95%CI 0.13-6.03. p=0.89). Conclusion UST intensification proves to be an effective long-term optimization strategy in CD, without an apparent correlation with higher serum drug levels in our series.

gastroenterology & hepatology
P944 Ustekinumab in refractory Ulcerative Colitis: single-center, real-world experience

C M Herrera De Guise,L F Mayorga Ayala,V Robles Alonso,X Serra Ruiz,E Céspedes Martínez,E Lastiri Gonzalez,Z Pérez Martínez,E Oller Jimenez,F Casellas,N Borruel Sainz

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1074

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab, an anti-interleukin 12/23 agent, was approved by the European Medicines Agency in 2019 as a treatment for moderate-to-severe ulcerative colitis (UC). Limited real-world data is available regarding the utilization of ustekinumab in UC, particularly medication persistence and escalation, which are indicators of medication performance in real-world settings. Our aim was to describe our experience with ustekinumab in refractory UC patients. Methods This was an observational single-center study on UC patients who received at least one intravenous dose of ustekinumab 16 weeks before data analysis due to active UC (Simple clinical colitis activity index (SCCAI)>5). Data regarding disease activity prior to and post-induction were analyzed. Patients were followed up until the last ustekinumab administration. Clinical response to therapy was assessed at 16, 24,52 weeks, and the end of follow-up. Response was defined as SCCAI<4, and remission as SCCAI≤2. Dose adjustment or IV maintenance was considered part of the treatment regimen. Patients who discontinued ustekinumab due to lack of therapeutic effect or worsening of UC were considered failures. When available, colonoscopy data was analyzed. Results Forty-seven patients who received ustekinumab for refractory UC were included. Thirty-eight percent were female, and 34% were former smokers. Median age was 46 [37.5-61.5]; 62% had extensive disease, and 15% had perianal disease. Ninety-three percent received at least one biologic before ustekinumab, and 24% had received a JAK inhibitor. Thirty-eight patients required dose escalation, and 11 were on maintenance IV. Clinical response at week 16 was achieved in 74% and remission in 46%. At 24 and 52 weeks, 65% and 61% were in remission, respectively. At the end of follow-up, 59% of patients had endoscopic remission (Endoscopic Mayo score ≤ 1). Sixty percent continued treatment during a mean follow-up of 12 months [6-21]. No variable was associated with risk of discontinuation. No serious adverse events were reported. Discontinuation of treatment was due to treatment failure in all cases. Conclusion Ustekinumab was effective for induction and maintenance in our cohort of UC patients, although a significant proportion required dose escalation. Drug persistence was higher than 50% during the follow-up. The safety profile of ustekinumab was similar to that in controlled studies and other real-world studies.

gastroenterology & hepatology
P673 Accelerated intravenous ustekinumab dosing as rescue therapy in Moderate- Severe Ulcerative Colitis

M D C Muñoz Villafranca,P Arreba,L Buendia,R O Higuera,M L López,N F Prado,L Irusta,M A Jiménez,M Aldama,M Santacruz,A Perez,P Rodriguez,A Bilbao,J Ortiz de Zárate

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0803

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is an accepted treatment for patients with moderate- severe Ulcerative Colitis (UC) following failure with corticosteroids and/or anti-TNF. Some studies suggest that intravenous (IV) administration, in an accelerated schedule, could improve outcomes in this difficult-to-manage group with a high risk of colectomy. Methods We conducted a retrospective analysis in patients with moderate-severe UC who received UST (IV) as rescue treatment, following failure with corticosteroids and infliximab. UST was administered intravenously, with an initial dose of 6mg/Kg followed by 130mg every four weeks. Clinical activity was determined by the Partial Mayo Score (PMS), and endoscopic activity by the Mayo Score (SM). Clinical Remission (CR) was defined as PMS<2, and Clinical Response (CRp) as a reduction in activity of ≥30%. Results The study included 17 patients, 8 (47%) women, 9 (52.9%) of whom were hospitalized at baseline, and 11/17 required transfusion or intravenous iron. According to PMS, clinical activity was severe in 16 (94.12%) and moderate in one. Endoscopic activity according to SM was severe in 13 (76.4%). Clinical remission and response were as follows: 1 (5.8%) / 7 (41.1%) patients respectively at week 4; 8 (47%) / 16 (94.1%) patients at week 12; and at week 26, 15 patients had completed the study, 10 (66.6%) in CR, and 12 (80%) in CRp. Ustekinumab was withdrawn in one case due to an infusion reaction, and one patient underwent colectomy. No independent predictors of response to UST were found in this study. Conclusion Intravenous ustekinumab in an accelerated dosing schedule is effective in moderate-severe UC, achieving clinical response in more than two-thirds of patients at week 26.

gastroenterology & hepatology
P690 Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity

J González Antuña,T Valdés Delgado,B Maldonado Pérez,L Castro Laria,V Merino Bohórquez,M Á Calleja Hernández,F Argüelles Arias

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0820

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Ustekinumab (UST) is an effective drug in inflammatory bowel disease (IBD). Monitoring Ustekinumab trough levels in μg/mL (USTTL) can assist in the clinical management of these patients. Our objective was to analyze USTTL in patients with IBD, establish cutoff points associated with clinical response and remission, and analyze factors related to higher levels. Methods Observational, retrospective, and single-center study that included patients with IBD receiving UST treatment with at least one level determination. Before the initiation of UST (baseline) and prior to level extraction (periods 1 and 2), clinical and analytical data were collected as follow: Harvey-Bradshaw Index (HBI) in Crohn's disease (CD), partial Mayo Index (pMayo) in ulcerative colitis (UC), fecal calprotectin (FC) and C-reactive protein (CRP). Median and interquartile range (IQR) were used for quantitative variables, and percentage (%) for qualitative variables. Univariate and bivariate analyses were performed for response and clinical remission rates using ROC curves. Results A total of 125 patients with at least one USTTL determination were included. Figure 1 illustrates their baseline characteristics. In period 1, 62.4% of patients were on subcutaneous maintenance, and the median USTTL was 3.1 (1.6-5.3). 64% of patients responded to treatment, with higher USTTL than non-responders [4.1 (2.0-6.2) vs. 2.1 (1.0-4.5); p=0.006]. 42.5% achieved clinical remission with higher USTTL than those who did not achieve it [4.0 (2.3-5.7) vs. 2.5 (1.2-5.2) p=0.039]. Furthermore, patients on subcutaneous maintenance* had lower USTTL than those on subcutaneous and intravenous intensification [2.2 (1.3-3.5)* vs. 7.4 (5.1-10.8) and vs. 5.3 (3.3-12); p<0.001 and p=0.03, respectively). In the 46 patients with two determinations, statistically significant differences were found between period 1 and period 2 in USTTL [3.4 (1.9-6.4) vs. 7.2 (4.7-11.7) p<0.001], HBI [8 (4-9) vs. 4 (4-4.3); p<0.001], pMayo [4.5 (3-5) vs. 1 (1-3.3); p=0,042], FC [700 (180-2000) vs. 400 (108-1571); p=0.032), and corticosteroid use (41.3% vs. 26.1%; p=0.024). ROC curves were calculated for response and clinical remission in period 2. The USTTL cutoff points were 4.25 and 6.025μg/mL for response and clinical remission, respectively (figure 2). Conclusion Similar to previously published studies with anti-TNF, high levels of USTTL are associated with increased clinical remission and response. Patients undergoing UST treatment may benefit from a change in dosage to increase levels and achieve clinical remission. The cutoff point obtained for clinical remission was 6 μg/mL. Therefore, the determination of USTTL in daily clinical practice is a useful tool for the treatment of patients with IBD.

gastroenterology & hepatology
Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease

Jiayin Yao,Xiang Peng,Yingkui Zhong,Tao Su,Adam Bihi,Junzhang Zhao,Tao Liu,Wei Wang,Pinjin Hu,Min Zhang,Min Zhi

DOI: https://doi.org/10.3389/fmed.2023.1105981

IF: 3.9

2023-07-24

Frontiers in Medicine

Abstract:Objectives Ustekinumab (UST) optimization strategies, including shortening intervals and intravenous reinduction, should be administered to patients with partial or loss of respond. Evidence comparing these types of optimization treatments is limited. We evaluated the efficacy and safety of weight-based UST intravenous reinduction in patients with refractory Crohn’s disease (CD). Methods This was a single-center retrospective observational study. Optimization strategies were designed for patients showing partial or loss of response to standardized UST therapy. Clinical, biochemical, and endoscopic response and remission rate were determined by Crohn’s disease activity index (CDAI), C-reactive protein (CRP) levels, and SES-CD evaluation. UST trough concentrations were detected and adverse events were recorded. Results A total of 128 patients receiving UST optimization therapies were included, with 105 patients administered shortening intervals of q8w or q4w, and 23 receiving intravenous reinduction followed by subcutaneous q8w or q4w. The follow-up duration for the shortening interval and reinduction cohorts were 15.0 (10.0, 31.0) and 23.0 (13.0, 70.0) weeks, respectively. A significant CDAI delta variation pre-and post-treatment could be found between groups [17.0 (−4.4, 65.9) vs. 69.0(10.7, 151.0), p = 0.013]. the trough concentration of UST increased [2.5 (1.3, 5.3) vs. 1.1 (0.5, 2.3), p = 0.001] after intravenous reinduction. Clinical and endoscopic remission were achieved in 69.6 and 31.8% of patients in the intravenous reinduction cohort, and 62.9 and 22.2% of patients in the shortening interval cohort, respectively. No significant difference was found between groups regarding safety. Conclusion Intravenous reinduction brought about favorable recapture of clinical and endoscopic remission, and should have significant priority over the strategy of merely shortening drug intervals, which should be launched before switching to other biologics targeting different inflammatory pathways. Clinical Trial Registration: identifier NCT04923100. https://classic.clinicaltrials.gov/ct2/show/NCT04923100?id=04923100&draw=2&rank=1

medicine, general & internal
Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease

Cristina Suárez Ferrer,José Arroyo Argüelles,Jose Luis Rueda García,Laura García Ramírez,Eduardo Martin Arranz,María Sánchez Azofra,Joaquín Poza Cordón,Jesús Noci Belda,Maria Dolores Martin-Arranz

DOI: https://doi.org/10.3390/jcm13030669

IF: 3.9

2024-01-24

Journal of Clinical Medicine

Abstract:Background: The rates of clinical and biochemical responses in Crohn's disease (CD) patients treated with intravenous (IV) ustekinumab (UST) intensification are scarcely described. Methods: Patients with diagnosis of CD who were under intensified IV ustekinumab treatment (130 mg every 4 weeks) were retrospectively included, evaluating the clinical and biochemical response 12 weeks after the change in treatment regimen (switch from SC to IV), as well as the serum levels of the drug. Results: Twenty-seven patients, all of whom had transitioned to intensified intravenous ustekinumab treatment due to a secondary loss of response to the drug, were included in the retrospective analysis. At the baseline visit, prior to changing IV UST, differences in levels were observed between intensified and non-intensified patients (7216 vs. 2842 ng/mL, p = 0.00005). However, no significant differences were found between these two groups 12 weeks after IV intensification (7949 vs. 7937 ng/mL; p = 0.99). In patients with previous intensified UST SC, a decrease in fecal calprotectin was observed 12 weeks after starting IV intensification, going from a mean of 1463 ug/g to 751 ug/g, although the differences were not significant (p = 0.14). Conclusion: In our experience, intensifying treatment with IV UST leads to clinical and biochemical improvements in CD patients with a secondary loss of response to SC maintenance with this drug, and an increase in drug levels was observed 12 weeks after IV UST intensification.

medicine, general & internal
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

María Chaparro,Iria Baston-Rey,Estela Fernández-Salgado,Javier González García,Laura Ramos,María Teresa Diz-Lois Palomares,Federico Argüelles-Arias,Eva Iglesias Flores,Mercedes Cabello,Saioa Rubio Iturria,Andrea Núñez Ortiz,Mara Charro,Daniel Ginard,Carmen Dueñas Sadornil,Olga Merino Ochoa,David Busquets,Eduardo Iyo,Ana Gutiérrez Casbas,Patricia Ramírez de la Piscina,Marta Maia Boscá-Watts,Maite Arroyo,María José García,Esther Hinojosa,Jordi Gordillo,Pilar Martínez Montiel,Benito Velayos Jiménez,Cristina Quílez Ivorra,Juan María Vázquez Morón,José María Huguet,Yago González-Lama,Ana Isabel Muñagorri Santos,Víctor Manuel Amo,María Dolores Martín-Arranz,Fernando Bermejo,Jesús Martínez Cadilla,Cristina Rubín de Célix,Paola Fradejas Salazar,Antonio López San Román,Nuria Jiménez,Santiago García López,Anna Figuerola,Itxaso Jiménez,Francisco José Martínez Cerezo,Carlos Taxonera,Pilar Varela,Ruth de Francisco,David Monfort,Gema Molina Arriero,Alejandro Hernández Camba,Francisco Javier García-Alonso,Manuel Van Domselaar,Ramón Pajares Villarroya,Alejandro Núñez,Francisco Rodríguez Moranta,Ignacio Marín-Jiménez,Virginia Robles Alonso,María del Mar Martín Rodríguez,Patricia Camo-Monterde,Iván García Tercero,Mercedes Navarro Llavat,Lara Arias García,Daniel Hervías Cruz,Sara Sulleiro,Cynthia Novella,Eugenia Vispo,Manuel Barreiro-de Acosta,Javier P Gisbert

DOI: https://doi.org/10.1093/ibd/izab357

2022-02-15

Inflammatory Bowel Diseases

Abstract:Abstract Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice. Methods A retrospective, multicentre study was conducted in Spain in patients with active CD who had received ≥1 intravenous dose of ustekinumab for ≥6 months. Primary outcome was ustekinumab retention rate; secondary outcomes were to identify predictive factors for drug retention, short-term remission (week 16), loss of response and predictive factors for short-term efficacy and loss of response, and ustekinumab safety. Results A total of 463 patients were included. Mean baseline Harvey-Bradshaw Index was 8.4. A total of 447 (96.5%) patients had received prior biologic therapy, 141 (30.5%) of whom had received ≥3 agents. In addition, 35.2% received concomitant immunosuppressants, and 47.1% had ≥1 abdominal surgery. At week 16, 56% had remission, 70% had response, and 26.1% required dose escalation or intensification; of these, 24.8% did not subsequently reduce dose. After a median follow-up of 15 months, 356 (77%) patients continued treatment. The incidence rate of ustekinumab discontinuation was 18% per patient-year of follow-up. Previous intestinal surgery and concomitant steroid treatment were associated with higher risk of ustekinumab discontinuation, while a maintenance schedule every 12 weeks had a lower risk; neither concomitant immunosuppressants nor the number of previous biologics were associated with ustekinumab discontinuation risk. Fifty adverse events were reported in 39 (8.4%) patients; 4 of them were severe (2 infections, 1 malignancy, and 1 fever). Conclusions Ustekinumab is effective and safe as short- and long-term treatment in a refractory cohort of CD patients in real-world clinical practice.

gastroenterology & hepatology
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study

M Chaparro,S Sulleiro,I Bastón-Rey,C Rodríguez,I García-Tercero,P Ramírez,S García-López,M Rojas-Feria,A Gutiérrez,J M Huguet Malavés,M F García-Sepulcre,B Sicilia,F Bermejo,F Rodríguez-Moranta,F Argüelles,I Marín,E Leo,M Arroyo,M J García,J M Vázquez,D Ginard,J Martínez Cadilla,C Rubín de Célix,A García-Herola,A Hernández-Camba,M D Martín-Arranz,S Riestra,P Varela,B Velayos,D Busquets,C Dueñas,E Fernández-Salgado,P Martínez-Montiel,M T Diz-Lois,Y González-Lama,A Muñagorri,M Navarro-Llavat,C Guisado,M Barreiro-de Acosta,J P Gisbert

DOI: https://doi.org/10.1093/ecco-jcc/jjz203.757

2020-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Post-marketing data are required to confirm the durability and the long-term benefit and safety of UST in CD in clinical practice. Our aims were: (1) to evaluate the retention rate of UST in CD patients and to identify predictive factors of UST discontinuation; (2) to assess UST short-term effectiveness; (3) to analyse the durability of the response to UST in the long-term; and (4) to evaluate the safety of UST in clinical practice. Methods Retrospective, multicentre study (>60 centres). Patients with active CD [(Harvey–Bradshaw (HBI) >4)] that received at least one dose of UST intravenously before July 2018 were included. Clinical activity plus biochemical parameters were assessed at every UST administration. Clinical remission was defined as HBI score ≤4, and clinical response as a decrease in HBI ≥3 points. Loss of efficacy was defined as reappearance of symptoms that led to intensify the treatment dose, add another medication to control CD, switching or surgery in patients with short-term remission. The retention rate of UST treatment and the cumulative incidence of loss of efficacy were evaluated by survival curves, and predictive factors were assessed by Cox-regression. The short-term response was evaluated at week 8 and after the induction (week 16). Factors associated with short-term remission were assessed by multivariate analysis. Adverse events were recorded. Data quality was assured by remote monitoring. Results 331 CD patients have been included up to date (Table 1). The incidence rate of UST discontinuation was 15% per patient-year of follow-up: 8%, 13% and 20% at 6, 12 and 18 months (Figure 1). Previous surgery was the only factor associated with a higher risk of UST discontinuation [Hazard ratio (HR) = 2.03, 95% confidence interval (CI) = 1.1–3.6]. Short-term efficacy is shown in Figure 2. Previous surgery (OR = 0.3, 95% CI = 0.2–0.6) and higher HBI score at baseline (OR = 0.8, 95% CI=0.8–0.9) were associated with an impaired response to UST at week 16. The cumulative incidence of loss of response was 32% per-patient-year of follow-up (Figure 3); A higher HBI score at baseline was associated with a higher risk of losing response (HR = 1.2, 95% CI = 1.1–1.3). Neither the concomitant treatment with immunosuppressants nor the number of previous biologics were associated with UST short- and long-term benefit. Thirty adverse events were reported in 25 (7%) patients (Table 2). Conclusion Sustain is the largest real clinical practice study of UST to treat CD patients with the longest follow-up reported to date. UST was demonstrated to be effective in real-world use in the short and long run. Safety was consistent with the known profile of UST.
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

María Chaparro,Sandra Hermida,Diana Acosta,Agnès Fernández-Clotet,Manuel Barreiro-de Acosta,Álvaro Hernández Martínez,Maite Arroyo,Marta Maia Bosca-Watts,M Teresa Diz-Lois Palomares,Luis Menchén,Jesús Martínez Cadilla,Eduardo Leo-Carnerero,Carmen Muñoz Villafranca,Mónica Sierra-Ausín,Yago González-Lama,Sabino Riestra,Pau Sendra Rumbeu,M José Cabello Tapia,Irene García de la Filia,Raquel Vicente,Daniel Ceballos,Ramón Pajares Villarroya,Patricia Ramírez de la Piscina,María Dolores Martín-Arranz,Laura Ramos,Alexandra Ruiz-Cerulla,Teresa de Jesús Martínez-Pérez,Elena San Miguel Amelivia,Xavier Calvet,José María Huguet,Alma Keco-Huerga,Rufo H Lorente Poyatos,José Fernando Muñoz,Ángel Ponferrada-Díaz,Beatriz Sicilia,Pedro Delgado-Guillena,Elena Gómez Delgado,Francisco J Rancel-Medina,Horacio Alonso-Galán,Belén Herreros,Montserrat Rivero,Pilar Varela,Fernando Bermejo,Marifé García Sepulcre,Leticia Gimeno-Pitarch,Lilyan Kolle-Casso,Lucía Márquez-Mosquera,Pilar Martínez Tirado,Cynthia Ramírez,Eva Sesé Abizanda,Carmen Dueñas Sadornil,Hipólito Fernández Rosáenz,Ana Gutiérrez Casbas,Rosa Eva Madrigal Domínguez,Óscar Nantes Castillejo,Yolanda Ber Nieto,Belén Botella Mateu,Santiago Frago Larramona,Pilar López Serrano,José María Rubio Mateos,Sandra Torrá Alsina,Eduardo Iyo,José Luis Fernández Forcelledo,Luis Hernández,María Carmen Rodríguez-Grau,David Monfort Miquel,Manuel Van Domselaar,Carmen López Ramos,M Jesús Ruiz Barcia,Javier P Gisbert,ULISES study group

DOI: https://doi.org/10.1111/apt.18230

Abstract:Background: Ustekinumab is approved for ulcerative colitis (UC). Aims: To assess the durability of ustekinumab in patients with UC and its short-term effectiveness, durability and tolerability in clinical practice. Methods: Retrospective, multicentre study of patients who had received their first ustekinumab dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only patients with active disease at the start of ustekinumab treatment were considered in the effectiveness analysis. Patients who stopped ustekinumab before their last visit were considered not to be in subsequent remission. Results: We included 620 patients; 155 (25%) discontinued ustekinumab during follow-up (median 12 months). Rate of discontinuation was 20% per patient-year of follow-up. Anaemia at baseline (hazard ratio, HR 1.5; 95% confidence interval [CI] 1.1-2.1), steroids at baseline (HR 1.5; 95% CI 1.06-2.08) and more severe clinical activity at baseline (HR 1.5; 95% CI 1.09-2.06) were associated with higher risk of discontinuation. At the end of induction, 226 (40%) patients were in steroid-free clinical remission. Moderate-severe vs mild disease activity at baseline (odds ratio [OR] 0.3; 95% CI 0.2-0.5), male sex (OR 0.5; 95% CI 0.4-0.8), and increased number of previous biologics (OR 0.6; 95% CI 0.6-0.8) were associated with lower likelihood of steroid-free clinical remission at week 16. One hundred and seventy-six patients (28%) had at least one adverse event. We observed no negative impact of ustekinumab on extraintestinal manifestations and/or immune-mediated diseases. Conclusions: Ustekinumab durability in UC was relatively high, and treatment was effective in highly refractory patients. The safety profile was consistent with previous studies.

Quantitative In Situ Analysis of the Human Anterior Cruciate Ligament and Midsubstance Cross Sectional Area

P650 Optimization through iv maintenance with ustekinumab in Inflammatory Bowel Disease. Efficacy and adjusted regimen in real world

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing

P740 Results at 52 weeks of Intravenous Ustekinumab as Maintenance Treatment in Patients with Loss of Response to Subcutaneous Doses: A Multicenter Retrospective Observational Study

P895 Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel Disease

P994 Single center assessment of intravenous ustekinumab maintenance in Crohn’s disease

P863 Prospective outcome following ustekinumab treatment in a real-world cohort of inflammatory bowel disease patients

P605 Intravenous Ustekinumab maintenance treatment is effective in patients with Crohn’s Disease

P334 Effectiveness and safety of ustekinumab in Crohn’s disease: short and long-term results of a multi-refractory cohort

High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease

DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study

P528 Re-induction of intravenous ustekinumab to maintain drug persistence. A UK experience

P531 Long-Term Evaluation of Intensified Ustekinumab in Crohn's Disease: Real-Life Results

P944 Ustekinumab in refractory Ulcerative Colitis: single-center, real-world experience

P673 Accelerated intravenous ustekinumab dosing as rescue therapy in Moderate- Severe Ulcerative Colitis

P690 Monitoring ustekinumab levels in Inflammatory Bowel Disease in clinical practice: a window of opportunity

Extra intravenous Ustekinumab reinduction is an effective optimization strategy for patients with refractory Crohn’s disease

Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study

P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study

Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study